Completed PHASE3 INTERVENTIONAL 2-arm NCT01404169

A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease

Sponsor: Eisai Limited

Interventions E2020 Placebo

Updated 7 times since 2017 Last updated: Mar 7, 2017 Started: Sep 30, 2011 Primary completion: Jul 31, 2014 Completion: Sep 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Alzheimer's Type Dementia, this trial is completed. The trial is conducted by Eisai Limited and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Mar 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Mar 2017 [monthly]

Completed PHASE3

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Limited

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changsha, China , Chengdu, China , Chongqing, China , Guangzhou, China , Hangzhou, China , Jinan, China , Kunming, China , Nanchang, China , Nanjing Jiangsu, China and 7 more locations